| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
DLin-M-C4-DMA does not have a specific biological receptor target. As an ionizable cationic lipid, its primary function is to facilitate the encapsulation and intracellular delivery of nucleic acids. At physiological pH, the lipid is largely neutral, but it becomes positively charged in the acidic environment of the endosome. This property enables endosomal escape, allowing the nucleic acid cargo to be released into the cytoplasm. Its pKa of 6.93 is optimized for this function.
|
|---|---|
| ln Vitro |
In vitro, DLin-M-C4-DMA is used to formulate lipid nanoparticles (LNPs) for nucleic acid delivery. LNPs containing DLin-M-C4-DMA can encapsulate siRNA or mRNA and deliver them to cells in culture. The ionizable nature of the lipid facilitates endosomal escape, which is a critical step for the effective delivery of nucleic acid therapeutics. The compound's ability to complex with and protect nucleic acids is assessed in these in vitro studies.
|
| ln Vivo |
In vivo, DLin-M-C4-DMA-containing LNPs have been shown to be effective for nucleic acid delivery. Lipid nanoparticles containing DLin-MC4-DMA and encapsulating siRNA for the gene encoding mouse coagulation factor VII (F7) reduce its gene expression levels in mice. This demonstrates the compound's utility in achieving functional delivery of siRNA to target tissues in vivo.
|
| Enzyme Assay |
In vitro assays for DLin-M-C4-DMA typically involve the formulation of lipid nanoparticles (LNPs) and the assessment of their nucleic acid encapsulation efficiency, size, and zeta potential. The pKa of the lipid is determined using a TNS (2-(p-toluidino)naphthalene-6-sulfonic acid) binding assay. The ability of the LNPs to deliver functional nucleic acids is assessed in cell culture by measuring the knockdown of a target gene (for siRNA) or the expression of a reporter protein (for mRNA).
|
| Cell Assay |
Cellular assays for DLin-M-C4-DMA typically involve treating cells with LNPs formulated with the lipid and encapsulating a nucleic acid cargo. The efficiency of delivery is measured by assessing the functional outcome, such as gene knockdown (for siRNA) or protein expression (for mRNA). Cytotoxicity is also evaluated to ensure the formulation is well-tolerated by cells.
|
| Animal Protocol |
In vivo animal studies for DLin-M-C4-DMA typically involve the intravenous administration of LNP formulations to mice. The efficacy of the formulation is assessed by measuring the reduction in target gene expression (e.g., Factor VII) in the liver or by evaluating the therapeutic effect in a disease model. Pharmacokinetics and biodistribution of the LNPs may also be evaluated.
|
| ADME/Pharmacokinetics |
DLin-M-C4-DMA is an ionizable cationic lipid with a pKa of 6.93. It has a molecular weight of 656.1 g/mol and is supplied as a liquid. It is soluble in chloroform and methanol and is typically stored at -20°C. Detailed pharmacokinetic parameters are not available in the public domain but are characteristic of ionizable lipids used in LNP formulations.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for DLin-M-C4-DMA in the available literature. As a research chemical, it should be handled with standard safety precautions. The compound is not approved for human therapeutic use. Toxicity studies would be required if the compound were to be used in clinical formulations.
|
| References | |
| Additional Infomation |
DLin-M-C4-DMA (DLin-MC4-DMA) is a synthetic ionizable cationic lipid used for nucleic acid delivery. It has a pKa of 6.93 and a molecular weight of 656.1 g/mol. LNPs containing this lipid have been shown to reduce gene expression in mice, demonstrating their in vivo efficacy for siRNA delivery.
|
| Exact Mass |
655.627
|
|---|---|
| CAS # |
1226909-66-5
|
| PubChem CID |
58559556
|
| Appearance |
Colorless to light yellow liquid
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
47
|
| Complexity |
702
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\\C/C=C\\CCCCCCCCC(OC(=O)CCCCN(C)C)CCCCCCCC/C=C\\C/C=C\\CCCCC
|
| InChi Key |
QNUBVWOFCJNYJO-KWXKLSQISA-N
|
| InChi Code |
InChI=1S/C44H81NO2/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-39-43(47-44(46)41-37-38-42-45(3)4)40-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h13-16,19-22,43H,5-12,17-18,23-42H2,1-4H3/b15-13-,16-14-,21-19-,22-20-
|
| Chemical Name |
[(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 5-(dimethylamino)pentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~152.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.81 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
